Although our use of additional tumor models further validated the paradigm of host anti-tumor resistance in the Mertk-/-V1 mice, we surprisingly also discovered that Mertk ablation is not sufficient for resistance against YUMM1.7 and GL261. The gene discussed is MERTK; the disease is neoplasm.